(777.6) The Flavonoid Troxerutin Prevents Tissue Damage and the Alteration of Cellularity Residing in Intestinal Mucositis by 5-Fluorouracil
Tuesday, April 5, 2022
10:15 AM – 12:15 PM
Location: Exhibit/Poster Hall A-B - Pennsylvania Convention Center
Poster Board Number: C24 Introduction: AAA has separate poster presentation times for odd and even posters. Odd poster #s – 10:15 am – 11:15 am Even poster #s – 11:15 am – 12:15 pm
Rafaella Pedroza (Pharmacy College, Federal University of Rio Grande do Norte - UFRN, Rio Grande do Norte), Paulo Rocha (Medical School, Federal University of Ceará - UFC, Ceará), Levi Carioca (Medical School, Federal University of Ceará - UFC, Ceará), Vitoria de Oliveira (Nutrition College, State University of Ceará - UECE, Ceará), Paulo Pimentel (Medical School, Federal University of Ceará - UFC, Ceará), Lázaro Fideles (Postgraduate Program in Morphofunctional Sciences, Medical School, Federal University of Ceará – UFC, Ceará), Gilberto Cerqueira (Postgraduate Program in Morphofunctional Sciences, Medical School, Federal University of Ceará – UFC, Ceará), João de Miranda (Postgraduate Program in Morphofunctional Sciences, Medical School, Federal University of Ceará – UFC, Ceará, Postgraduate Program in Morphofunctional Sciences, Medical School, Federal University of Ceará – UFC, Ceará)
Presenting Author Pharmacy College, Federal University of Rio Grande do Norte - UFRN, Rio Grande do Norte
Intestinal mucositis, characterized by inflammatory and/or ulcerative processes, occurs due to cellular and tissue damage following treatment with 5-fluorouracil (5-FU). Troxerutin (TRX), a semi-synthetic flavonoid extracted from Dimorphandra gardneriana, has been reported as a potent anti-inflammatory agent. The present study aimed to evaluate the effect of TRX on 5-fluorouracil-induced intestinal mucositis in Swiss mice. The mice (25-30g) were separated into 3 groups (n = 6): Saline group (NaCl 0.9%), 5-FU group, TRX group (100mg/kg TRX, orally). All animals, except the Saline group, received 5-FU at the concentration of 450 mg/kg in the first experimental protocol. Duodenal portions were removed for evaluation of mucositis by analysis of histopathological damage and cellularity of resident cells of the intestinal mucosa (mast cells and goblet cells). The results of the histopathological analysis demonstrated that 5-FU promoted structural alterations of the intestinal mucosa (p lt;0.05), evidenced by the reduction of villi height, deepening of the crypts, and TRX treatment (100 mg/kg) prevented the 5-FU-induced histopathological changes (p lt;0.05). Regarding cellularity, TRX decreases 5-FU-induced mast cell infiltration (p lt;0.05), as well as decreases cell lineage degranulation and, regarding goblet cell count, mucus-producing cells, TRX prevented the decrease of these cells (p lt;0.05), which is a problem promoted by the 5-FU. Our findings suggest that TRX at a concentration of 100 mg/kg had chemopreventive effects on 5-FU-induced intestinal mucositis due to the prevention of histological damage and maintenance of resident cellularity in the intestinal mucosa.